Literature DB >> 11122801

The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

A E Selman1, L J Copeland.   

Abstract

Because noninvasive methods like ultrasound scanning or computed tomography cannot detect small-volume residual tumor, second-look laparotomy has been recommended for evaluation of treatment response in ovarian cancer. The use of cancer antigen 125 to monitor the course of the disease during treatment is widely accepted. The tumor marker has prognostic value, but its ability to detect small volume of disease is limited. Second-look laparotomy appears to have a limited role in the management of ovarian cancer patients, especially in the context of ineffective second-line therapy.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11122801     DOI： 10.1007/s11912-999-0013-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  45 in total

1.  Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.

Authors:  A Gadducci; E Sartori; T Maggino; P Zola; F Landoni; A Fanucchi; N Palai; C Alessi; A M Ferrero; S Cosio; R Cristofani
Journal:  Gynecol Oncol       Date:  1998-02       Impact factor: 5.482

2.  CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s.

Authors:  R E Buller; S Vasilev; P J DiSaia
Journal:  Am J Obstet Gynecol       Date:  1996-04       Impact factor: 8.661

3.  Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.

Authors:  A P Makar; G B Kristensen; O P Børmer; C G Tropé
Journal:  Gynecol Oncol       Date:  1993-04       Impact factor: 5.482

Review 4.  CA 125 in gynecological pathology--a review.

Authors:  P Kenemans; C A Yedema; G G Bon; S von Mensdorff-Pouilly
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1993-04       Impact factor: 2.435

5.  Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.

Authors:  H W de Bruijn; K A ten Hoor; H Boonstra; J Marrink; M Krans; J G Aalders
Journal:  Tumour Biol       Date:  1993

6.  Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.

Authors:  S C Rubin; W J Hoskins; P E Saigo; D Chapman; T B Hakes; M Markman; B Reichman; L Almadrones; J L Lewis
Journal:  Gynecol Oncol       Date:  1991-08       Impact factor: 5.482

7.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

Review 8.  Second-look laparotomy in epithelial ovarian cancer.

Authors:  L J Copeland; L Vaccarello; G S Lewandowski
Journal:  Obstet Gynecol Clin North Am       Date:  1994-03       Impact factor: 2.844

9.  Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.

Authors:  H J Long; R A Nelimark; J Q Su; S C Garneau; R Levitt; R M Goldberg; M A Poon; J W Kugler
Journal:  Gynecol Oncol       Date:  1994-08       Impact factor: 5.482

10.  Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.

Authors:  A Gadducci; P Zola; F Landoni; T Maggino; E Sartori; T Bergamino; R Cristofani
Journal:  Gynecol Oncol       Date:  1995-07       Impact factor: 5.482
View more
  2 in total

1.  Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates.

Authors:  Bryan Q Spring; Adnan O Abu-Yousif; Akilan Palanisami; Imran Rizvi; Xiang Zheng; Zhiming Mai; Sriram Anbil; R Bryan Sears; Lawrence B Mensah; Ruth Goldschmidt; S Sibel Erdem; Esther Oliva; Tayyaba Hasan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-26       Impact factor: 11.205

2.  In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.

Authors:  W Zhong; J P Celli; I Rizvi; Z Mai; B Q Spring; S H Yun; T Hasan
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.